



**Corrigendum to Commission Implementing Regulation (EU) 2026/351 of 18 February 2026
renewing the approval of the active substance spinosad in accordance with Regulation (EC)
No 1107/2009 of the European Parliament and of the Council and amending Commission
Implementing Regulation (EU) No 540/2011**

(Official Journal of the European Union L, 2026/351, 19 February 2026)

On page 5, in Annex I, in the first paragraph of the column 'Specific provisions':

for: 'For the implementation of the uniform principles as referred to in Article 29(6) of Regulation (EC) No 1107/2009, the conclusions of the renewal report on spinosad of 11 December 2025, and in particular, Appendices I and II thereto, shall be taken into account.'

read: 'For the implementation of the uniform principles as referred to in Article 29(6) of Regulation (EC) No 1107/2009, the conclusions of the renewal report on spinosad of 21 January 2026, and in particular, Appendices I and II thereto, shall be taken into account.'

On page 7, in Annex II, in point (2), in the amendments to Part B of the Annex to Implementing Regulation (EU) No 540/2011, in the first paragraph of the column 'Specific provisions':

for: 'For the implementation of the uniform principles as referred to in Article 29(6) of Regulation (EC) No 1107/2009, the conclusions of the renewal report on spinosad of 11 December 2025, and in particular, Appendices I and II thereto, shall be taken into account.'

read: 'For the implementation of the uniform principles as referred to in Article 29(6) of Regulation (EC) No 1107/2009, the conclusions of the renewal report on spinosad of 21 January 2026, and in particular, Appendices I and II thereto, shall be taken into account.'
